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Herpes zoster (HZ; shingles) is a viral disease characterized by a painful unilateral rash involving one or
two adjacent dermatomes. HZ results from reactivation of the varicella zoster virus (VZV) acquired
during chickenpox. Following this primary VZV infection, the virus establishes latency in sensory nerve
ganglia, until it reactivates decades later. The rash usually heals within 2e4 weeks, but some individuals
experience residual neuropathic pain, known as postherpetic neuralgia (PHN), for months or even years,
which can seriously impact their quality of life. We reviewed the epidemiological data for PHN in Europe
since 2000 after the introduction of antiviral drugs. The overall lifetime risk for HZ was 23e30% and
increased to 50% in those >80 years old. Deﬁning PHN as pain persisting 3 months after rash onset,
between 10% and 30% of patients with HZ developed PHN; this increased to 60e70% in those age 60
years. Some trials have reported that antiviral agents given soon after rash onset may prevent PHN.
Vaccination programs with a zoster vaccine have been shown to prevent PHN, particularly in older
patients. The various deﬁnitions used for PHN in different studies make it difﬁcult to acquire a mean-
ingful measurement of the true burden of PHN. In addition, comparisons between various studies and
the prevalence and incidence data from different countries are difﬁcult, because of this heterogeneity.
This article provides a balanced overview of the important clinical and epidemiological studies carried
out with respect to the deﬁnition, prevention, and treatment of this debilitating condition.
Copyright  2013, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
LLC.
 
Open access under CC BY-NC-ND license.1. Introduction
Herpes zoster (HZ), or shingles, is the clinical manifestation of
the reactivation of latent varicella zoster virus (VZV) in the dorsal
root ganglia, which can occur up to several decades after the initial
infectionwith varicella virus (chickenpox; Fig. 1).1 A decline in VZV-
speciﬁc immunity, either due to natural immunosenescence with
aging or immunosuppression secondary to certain diseases (ma-
lignancies, HIV/AIDS) or immunosuppressant therapy, is known to
favor symptomatic reactivation of VZV. Stress can also induce this
reactivation process.
HZ is characterized by a vesicular skin rash that usually heals
within 2e4 weeks and which is often preceded or accompanied by
acute pain or itching. In some individuals, pain may persist for
months or years after the rash has resolved, a chronic pain situationHospital, BP Lyon-Montchat,
linical Gerontology & Geriatrics. Pknown as postherpetic neuralgia (PHN). Other complications of HZ
include secondary bacterial infection, ophthalmic complications,
motor paresis, cerebral angiitis, Guillain-Barré syndrome, and
visceral dissemination of the virus.2 However, PHN is the most
common and debilitating complication of HZ. It can have a devas-
tating impact on patients’ quality of life and, in very severe cases,
can lead to drug dependency, depression, or even suicide.3
In temperate regions without a varicella vaccination program,
>95% of the population will have had varicella before they are 30
years of age4; consequently, most of the population is at risk of
developing HZ and thus PHN. The potential burden of illness from
HZ and PHN is high and thus a major public health problem. HZ and
PHN result in signiﬁcant costs for patients, healthcare providers,
and society as a whole.5,6
Reports in the literature on the proportion of patients who
present with HZ and consequently develop PHN vary considerably,
depending on the deﬁnition of PHN and the study design. Histori-
cally, PHN has been reported to occur in 9e34% of patients who
have HZ.7 It is likely that the incidence of PHN is similar across
temperate regions, but there are few published studies fromublished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
Fig. 1. Lifetime changes in cell-mediated immunity to varicella zoster virus. Varicella is
the primary infection caused by the varicella zoster virus (VZV) and results in the
induction of VZV-speciﬁc memory T-cells after initial exposure (solid line on graph).
This immunity to VZV may be boosted periodically by subsequent exposure to varicella
or subclinical reactivation of the latent virus (see initial peaks on graph). The number
of VZV-speciﬁc memory T cells decline with age. The risk of herpes zoster (HZ) in-
creases if the decline falls below a threshold (dashed line on graph). HZ is associated
with an increase in the number of VZV-speciﬁc T-cells. Administration of zoster vac-
cine to the elderly may prevent the number of VZV-speciﬁc T cells from declining
below the threshold for HZ occurrence (dotted line on graph). Note. From “Aging,
immunity, and the varicella-zoster virus,” by A. Arvin, 2005, N Engl J Med, 352, p. 2267.
Copyright 2005, Massachusetts Medical Society. Reproduced with permission.
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describe the epidemiology of PHN in Europe after the introduction
of antiviral drugs, based on a literature review of epidemiological
studies, clinical trials, and reviews published since 2000, and to
brieﬂy review the opportunities for prevention and treatment.Fig. 2. Epidemiology of herpes zoster (HZ) and post-herpetic neuralgia (PHN) (based
on data published in 2008). Note. From “Epidemiology and cost of herpes zoster and
post-herpetic neuralgia in the United Kingdom,” by A. Gauthier, J. Breuer, D. Carring-
ton, M. Martin, and V. Remy, 2009, Epidemiol Infect, 137, p. 41e42. Copyright 2009,
Cambridge Journals. Adapted with permission.2. Deﬁnition of PHN
Although PHN may persist for many years in some individuals,
the occurrence of PHN naturally decreases in the months after
resolution of the rash.5,8,9 A 12-month, community-based study
conducted in the United Kingdom showed that, among patients
with HZ, 95.8% of patients experienced pain at presentation, 38.2%
at 6 weeks, 27.4% at 3 months, 15.9% at 6 months, and 9.0% at 12
months.9 In another 12-month study of 1358 patients consulting
general practitioners for HZ, despite receiving antiviral drugs (94%
overall; 77% within 3 days after HZ rash onset) the prevalence of
pain was 43.2% at day 15, 11.6% at 3 months, 7.4% at 9 months, and
6% at 12 months.10 For patients aged>70 years, the painwas higher
at each time point: 48.1%, 14.3%, 9.3%, and 7.7%, respectively.10
PHN is indeed awell-known neuropathic pain syndrome, but its
deﬁnition remains controversial. There is no universal agreement
as to when HZ-associated pain becomes PHN or if pain intensity or
typology should be included in the deﬁnition. A single, interna-
tionally recognized deﬁnition of PHN would allow meaningful
measurement of the burden of illness, as well as comparison across
studies and countries. Some studies have identiﬁed three distinct
phases of zoster-associated pain (acute herpetic neuralgia, subacute
herpetic neuralgia, and PHN), and suggest that PHN should be
deﬁned as neuropathic pain persisting beyond 3 months after the
onset of the herpetic rash.11e13 This deﬁnition is consistent with the
distinction between acute and chronic pain proposed in the clas-
siﬁcation of chronic pain syndromes by the International Associa-
tion for the Study of Pain (IASP).14 By contrast, the International
Herpes Management Forum (IHMF) deﬁnes PHN as pain persisting
beyond 4 months from onset of the prodrome of HZ, without
reference to the type of pain (neuropathic or not).15
Deﬁnitions of PHN used in some clinical trials have included the
usual requirement for chronic pain after healing to be signiﬁcant,i.e., rated as3 on a scale ranging from 0 (“no pain”) to 10 (“pain as
bad as you can imagine”).16,17 It has been suggested that the deﬁ-
nition of PHN should be revised to include only cases of clinically
meaningful PHN, in which pain is sufﬁciently severe to produce
disability or require medical treatment [i.e., average daily pain
ratings over the previous 48 hours 30 on a 0e100 visual analog
scale (VAS) at 6 months after rash onset].18 This suggestion has
been countered on the basis that this stringent deﬁnition of PHN
would limit research on the prevention of PHN, because of difﬁ-
culties in recruiting enough patients into clinical trials.19 Further-
more, this deﬁnition may be regarded as dismissive of the
importance of pain rated >0 and <30 on the VAS to patients.
A neuropathic pain expert group in France proposed a deﬁnition
describing PHN as persistent pain at the involved site after the rash
has healed, displaying features of neuropathic pain.20 This deﬁni-
tion is based on the identiﬁcation of one or more clinical features of
neuropathic pain, i.e., the presence of spontaneous permanent
(burning, pressure) and/or paroxysmal pain (electric shocks), and/
or evoked pain (mechanical or thermal hyperalgesia and/or allo-
dynia).21 Moreover, painful symptoms occur in circumscribed
neurological areas in which a sensory deﬁcit can be demonstrated,
and may be associated with dysesthesia and/or paresthesia. In light
of the controversy surrounding the timing of PHN and the recent
deﬁnition of neuropathic pain,20 the absence of a latency period or
a speciﬁed duration of painmakes this deﬁnition a putative starting
point for expert discussion on a universally accepted deﬁnition.
3. Incidence of HZ and proportion of patients developing PHN
3.1. Incidence of HZ
The current estimated lifetime risk of developing HZ in Europe is
23e30%, with a reported lifetime risk of recurrence of <5%.4,6,22,23
The risk increases considerably with age, reaching 50% in in-
dividuals aged >80 years (Fig. 2).6,24e26 Immunocompromized in-
dividuals are at higher risk of developing HZ, even at a younger age.
In the general population of Europe, the overall annual incidence of
HZ is reported to be around 3 per 1000 population.27 However,
patient awareness of HZ is low in many countries in Europe, and
many cases of HZ are probably unreported.28 Recent estimates of
the annual incidence of HZ from several European countries range
from 1.6 per 1000 population to 5.2 per 1000 population.3,6,29e33
The annual incidence in France increased from 2.2 per 1000 in in-
dividuals <20 years of age to 2.4 per 1000 in 20e39-year-olds, 5.4
per 1000 in 40e59-year-olds, 9.9 per 1000 in 60e74-year-olds, and
12.8 per 1000 in individuals >74 years of age.3 Based on the esti-
mates of incidence rates, it is estimated that about 1.7 million cases
G. Mick, G. Hans / Journal of Clinical Gerontology & Geriatrics 4 (2013) 102e108104of HZ occur annually in the European Union (population, 460
million).4
3.2. Proportion of HZ patients who develop PHN
Estimates of the prevalence of PHN vary widely depending upon
the deﬁnition of PHN used, the study methodology, and the age
distribution of the study population.2 The prevalence of PHN
among patients aged >50 years with HZ reported in the literature
varies bymore than 25%, primarily as the result of differences in the
deﬁnition of PHN.4 In addition, the absence of International Sta-
tistical Classiﬁcation of Diseases and Related Health Problems (10th
revision: ICD-10) code for PHN makes it difﬁcult to extract infor-
mation from healthcare databases.
PHN deﬁned classically as pain persisting at 3 months after rash
onset has been reported to occur in 10e20% of patients with HZ.4e6
However, the prevalence and severity of PHN increase markedly
with increasing age (Fig. 2).7,24,34 The risk of developing PHN after
HZ infection may be as high as 60e70% among those 60 years of
age.26,35
Epidemiological data published since the year 2000 from seven
European countries (France, Germany, Iceland, Italy, The
Netherlands, Spain, and the United Kingdom) showing the per-
centage of patients with HZ developing PHN is summarized in
Table 1.5,6,9,29,30,36e40 Across countries in Europe, PHN deﬁned as
pain at 1 month after HZ rash onset has been reported to occur in
6.5e44.6% of patients, whereas, with a deﬁnition of pain at 3Table 1
Percentage of patients with herpes zoster (HZ) developing postherpetic neuralgia (PHN)
Country/reference
or study/database
Deﬁnition of PHN
1 mo 3
% o
Overall By age (y) Overall
France
Czernichow et al 200129 18.4 <50: 2.5
50: 25.0
Mick et al 201036 44 32.1
Germany
AOK 10.1 6.9
IMS 12.5 2.8e3.6
Iceland
Helgason et al 200037 <50: 5.6
50e59: 22.7
60e69: 39.2
70: 50.0
Italy
Di Legami et al 200733 17.4a
SIMG 9.4 7.2
The Netherlands
Opstelten et al 200230 6.5 44: 0.9
45e54: 3.9
55e64: 6.5
65e74: 10.7
75: 18.0
2.6
Spain
Cebrian et al 200838 32
Cebrian-Cuenca et al 201140 47.6 <50: 21
50e59: 40
60e69: 69
>70: 59
14.5
United Kingdom
Scott et al 20039 38.2b 27.4
Coen et al 200639 20.1b 9.6
Scott et al 20065 13.4
Gauthier et al 20096 19.5 13.7
AOK ¼ Allgemeine Ortskrankenkasse; IMS ¼ Intercontinental Marketing Services; SIMG
a Pain occurring within 2 months of the diagnosis of HZ.
b Pain at 6 weeks after rash onset.months after rash onset, PHN occurred in 2.6e32.9% of patients
(Table 1). Few European studies published since 2000 have re-
ported PHN beyond 3 months after rash onset, but long-term
studies of patients with HZ in Iceland and the United Kingdom
have shown a consistent reduction in the proportion of patients of
all ages experiencing PHN at 6 months and 12 months.5,9,37,39
Recent studies in Iceland and The Netherlands have, however,
shown a consistent age-related increase in the percentage of pa-
tients with HZ who develop PHN.30,37
4. Risk factors for developing PHN
Several risk factors for the development of PHN have been
identiﬁed. These include older age, presence of a prodrome prior to
rash, greater severity of rash, greater severity of acute pain,
ophthalmic involvement, and possibly female sex, psychological
stress, and concomitant disease such as diabetes mellitus.13,41,42
The age at which HZ appears is the principal risk factor for the
development of PHN. The risk of PHN increases dramatically with
age, as does the severity and duration of related pain.6,37,39,43,44 This
has been demonstrated in several European studies.6,9,10,29,30,45,47,49
In one study in Canada, functional status (i.e., limitation in per-
forming usual activities) prior to HZ was found to be an indepen-
dent predictor of PHN, in addition to age and severity of pain at
recruitment into the study.46 Female sex has also been reported to
be an independent risk factor for the development of HZ.47 How-
ever, whereas some studies have indicated a greater risk for womenin Europe.
(time of pain persistence from onset of zoster rash)
mo 6 mo 12 mo
f patients with HZ developing PHN
By age (y) Overall By age (y) Overall By age (y)
17.6
<50: 1.3
50e59: 3.8
60e69: 12.1
70: 28.1
<50: 0
50e59: 3.7
60e69: 4.5
70: 15.0
44: 0.3
45e54: 0.8
55e64: 2.9
65e74: 3.3
75: 9.0
<50: 0
50e59: 14
60e69: 26
>70: 19
9.0 5.9
15.9 9.0
6.9 4.6
5.4
¼ Società Italiana di Medicina Generale.
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this.6,13,30,37,39,43,48,49
5. Effect of HZ and PHN on quality of life
It has been reported in a literature review that acute HZ pain and
PHN can signiﬁcantly impair quality of life in the general popula-
tion. The quality of life in older persons, who are particularly con-
cerned by these pathologies, is more impaired, compared with
younger persons.50 In one patient-reported outcomes survey
involving over 11,000 participants, it was found that pain (both
acute HZ pain and PHN) disrupted many aspects of daily living,
including sleep, normal work, and mood.51 Some non-pain com-
plications, such as HZ ophthalmicus, can increase the risk of per-
manent physical deterioration. An acute episode of HZ in elderly
individuals may lead to permanent loss of independence.52 In a
French study, two-thirds of the patients reported that HZ had a
moderate to very serious impact on their daily lives.10 PHN also had
a negative impact on their psychological states and quality of life.10
6. Treatment of established PHN
Irrespective of the deﬁnition of PHN used, the proportion of
patients with HZ developing PHN remains high, despite therapeutic
advances in the treatment of HZ.6 The main therapeutic agents for
treating PHN are systemic drugs such as tricyclic antidepressants,
a2d-ligands (gabapentin and pregabalin), and opioids, or topical
agents such as lidocaine and capsaicin (Table 2).4,53e55 These drugs
can be used alone or in combination.56 Nevertheless, established
PHN is difﬁcult to manage and is frequently refractory to treatment.
Treatment of PHN is difﬁcult because no single therapy is
completely effective for numerous patients.56e58 Current therapies
often fail to provide signiﬁcant beneﬁt for about 50% of patients
with PHN.2,53 This may be because multiple pain mechanisms are
involved.15,44,59 Moreover, side effects and drug interactions are
particularly common in older patients receiving multiple medica-
tions, and may lead to discontinuation of therapy (Table 2).60,61
Recent European guidelines on the treatment of PHN published
by the European Federation of Neurological Societies (EFNS)
recommend that tricyclic antidepressants or a2d-ligands should be
used as ﬁrst-line treatment in patients with PHN.56 They also
recommend that lidocaine should be used as ﬁrst-line treatment in
the elderly, because of its excellent tolerability, despite its less
consistent results. As second choice treatments, the guidelines
recommend strong opioids or capsaicin; the long-term effects of
repeated application of the latter are unknown.56Table 2
Summary of interventions for the prevention and treatment of postherpetic neuralgia (P
Intervention Effectiveness
Prevention
Vaccination68 66.5% reduction of PHN incidence
Antiviral agents67 Reduction of PHN pain intensity and durati
but 20e30% of treated patients in clinical
Corticosteroids55 Ineffective in preventing PHN
Treatment of established PHN
Antiviral agents67 Weak evidence to suggest reduced intensit
Anticonvulsants15 Reduction in pain associated with PHN
Tricyclic antidepressants4,53 Reduction in pain associated with PHN, plu
action, may improve sleep disturbances a
Topical agents52 Lidocaine and capsaicin patches have been
provide some pain relief
Epidural therapies and nerve blocks Prolonged, but not single dose, epidural loc
has been shown to reduce pain7. Prevention of PHN
7.1. Antiviral agents
Antiviral agents are widely used in the treatment of HZ if patients
present early in the course of the disease (Table 2). European treat-
ment guidelines recommend theuseof antiviral drugs inpatients>50
years of agewithacuteHZpresentingwithin 72hours of rashonset, or
in patients who are in severe pain at any age.35,62e64 Treatment with
antiviral drugs within 72 hours of HZ rash onset aims to reduce viral
shedding and formation of new lesions, accelerate rash healing, and
reduce acute pain. Antiviral therapy also helps to minimize long-
lasting damage to nerves by inhibiting viral replication.
Lack of symptom awareness among patients and general practi-
tioners, as well as atypical presentation of HZ, often prevent timely
antiviral treatment, and some studies suggest that only 25e50% of
patients with HZ receive antiviral agents at an early stage.6,9,65 How-
ever, ina recent study inFrance involving1358patientswhoconsulted
their physician for HZ, 94% received antiviral therapy, with 77%
receiving treatment within 3 days of HZ rash onset.10 Awareness
programshave attempted to increaseunderstandingof the symptoms
ofHZ and the importance of the 72-hour “windowof opportunity” for
antiviral therapy.28 However, these efforts have had little impact on
the proportion of cases ofHZ treatedwith antiviral drugs, and delayed
presentation is still reported to be a signiﬁcantproblem.Nevertheless,
early administration of antiviral drugs (acyclovir, valacyclovir, famci-
clovir, and brivudin) to patients most at risk of developing PHN, has
been shown to reduce the duration and severity of PHN.6,66 A recent
Cochrane review analyzed results from six randomized controlled
trials, with a total of 1211 participants; ﬁve trials evaluated oral
acyclovir, and one trial with 419 participants evaluated oral famci-
clovir.66 They reported no signiﬁcant difference between the oral
acyclovir and control groups for the incidence of PHN 4 months [risk
ratio (RR)¼ 0.75; 95%conﬁdence interval (CI)¼ 0.51e1.11;p¼ 0.15] or
6months (RR¼ 1.05; 95% CI¼ 0.87e1.27; p¼ 0.62) after the onset of
the acute herpetic rash. Although there was some evidence for a
reduction in the incidence of pain 4 weeks after the onset of rash,
authors concluded that oral acyclovir was ineffective in reducing the
incidence of PHN deﬁned as pain lasting4 months after rash onset,
and that there is insufﬁcient evidence to support the use of other
antiviral drugs, such as oral famciclovir, for preventing PHN.67
7.2. Vaccination
A high-potency VZV vaccine (Zostavax) has been developed to
boost VZV-speciﬁc immunity and protect against HZ and PHN. TheHN).
Adverse effects
Vaccine is well tolerated and injection site reactions
are generally mild
on,
trials still develop PHN
Few adverse events
No serious adverse events
y and duration of PHN Signiﬁcant adverse events in older patients
Drowsiness, dizziness, ataxia, cognitive impairment
(especially in elderly patients)
s sedative
nd anxiety
Dizziness, sedation, dry mouth, constipation
shown to Some discomfort reported with capsaicin patches
al anesthetic Not practical for widespread use and associated
with risk of adverse effects
Table 3
Summary of results from the Singles Prevention Study (SPS) and the Short-term Persistence Substudy (STPS).17,69
Incidence in zoster
vaccine group per
1000 participants/y
Incidence in placebo
group per 1000
participants/y
Vaccine efﬁcacy
Herpes zoster PHN Herpes zoster PHN Herpes zoster point
estimate (95% CI)
PHN point estimate (95% CI)
SPS (0 e 4.9 y)17 5.4 0.46 11.1 1.39 51.3 (44.2; 57.6) 66.5 (47.5; 79.2)
STPS (3.3 e 7.8 y)69 8.4 0.70 14.0 1.78 39.6 (18.2; 55.5) 60.1 (e9.8; 86.7)
SPS and STPS (0 e 7.8 y)69 5.9 0.50 11.4 1.43 48.7 (42.0; 54.7) 64.9 (47.4; 77.0)
G. Mick, G. Hans / Journal of Clinical Gerontology & Geriatrics 4 (2013) 102e108106vaccine has been approved for use by the US Food and Drug
Administration (FDA) and the European Medicines Agency (EMA)
in all individuals 50 years of age. The efﬁcacy of the vaccine in
reducing the incidence of HZ and PHN and attenuating the severity
of PHN in cases of HZ was investigated in 38,546 individuals age
60 years.17,68 Over a mean follow-up period of 3.13 years, the
burden of illness due to HZ (a composite measure of incidence,
severity, and duration of pain and discomfort) was signiﬁcantly
reduced by 61.1%, the prevalence of PHN reduced by 66.5% (95%
CI ¼ 47.5e79.2), and the prevalence of HZ reduced by 51.3%
(Table 3). In addition, in a subanalysis on individuals 70 years of
age, it was demonstrated that the efﬁcacy of prevention of PHNwas
higher [66.8% (95% CI ¼ 43.3e81.3)]. A subsequent study moni-
toring 7320 vaccine recipients from the previous trial showed that
vaccine efﬁcacy (burden of illness due to HZ and incidence of HZ)
persists for up to 7 years postvaccination.69 The efﬁcacy, safety, and
immunogenicity of the vaccine were also assessed in 22,439 in-
dividuals aged 50e59 years old (Table 3).70 In this population, the
vaccine displayed a statistically signiﬁcant reduction in the inci-
dence of HZ by 69.8% (95% CI ¼ 54.1e80.6%) for up to 2 years. The
number of patients reporting one or more serious adverse event
was low and similar between the vaccine and placebo groups. A
recent systematic review from the Cochrane Collaboration (based
on the only published randomized controlled trials to date)
concluded that the vaccine did not show any efﬁcacy for prevention
of PHN over and above that for prevention of HZ.71 However, these
authors used the deﬁnition of PHN of 4 months of persistent
neuropathic pain after HZ rash onset, instead of 3 months. In the
original trial, the deﬁnition used was 3 months persistent neuro-
pathic pain after HZ rash onset; this deﬁnition has been accepted by
licensing agencies, e.g., the FDA in the United States and the EMA in
Europe. In addition, this Cochrane review did not perform an age-
stratiﬁed analysis. However, in the analyzed trial, vaccine efﬁcacy
against HZ decreased with age, but efﬁcacy for PHN remained
constant with age, thus additional vaccine efﬁcacy against PHN
would be expected to be age-dependent. This means that an age-
stratiﬁed analysis is needed to assess whether the vaccine
reduced the incidence of PHN beyond the reduction in PHN
resulting from the prevention of HZ.72 Finally, results from recent
modeling studies estimate that vaccination programs for preven-
tion of HZ and PHN in the UK, Belgium, and The Netherlandsmay be
considered cost-effective, especially within the 60e69-year-old age
group.73e78
7.3. Impact of childhood varicella vaccination on the incidence of HZ
Varicella vaccination has decreased the incidence of varicella
and varicella-related outcomes in children.79 Because shingles is
caused by reactivation of the varicella virus that remains dormant
after the primo-infection, and exposure to varicella is thought to
boost immunity against this reactivation, questions about the
impact of childhood varicella vaccination on the incidence of
shingles arise.80 Results from a more recent modeling study in the
UK suggest that if childhood vaccination coverage is high (i.e., 90%for the ﬁrst dose and 80% for the second), it is unlikely that there
will be an increase in the incidence of adult varicella.81 In addition,
analyses of data from an American healthcare database (Market-
Scan) show that although there has been an increase in the inci-
dence of HZ from 1993 to 2006, there is no evidence that this is due
to the childhood varicella vaccination program.78 To summarize,
there is no conclusive evidence that universal childhood varicella
vaccination has had an impact on the epidemiology of HZ. Long-
term surveillance studies are needed to improve our understand-
ing of the potential impact.8. Outlook for the future
In the absence of an internationally accepted deﬁnition for PHN
(particularly duration and severity of HZ-associated pain required
to qualify for PHN), it remains difﬁcult to assess the true prevalence
of PHN in Europe. Deﬁning PHN as neuropathic pain at the affected
site, after the rash has healed, may be a good starting point for a
discussion on a consensus deﬁnition. Recent studies in Europe used
various designs and different deﬁnitions of PHN, and hence, re-
ported proportions of patients with HZ developing PHN vary
considerably and comparisons across studies are difﬁcult (Table 1).
It is, however, currently estimated that >20% of patients >50 years
old with HZ will develop PHN.
Currently available medications do not prevent PHN, or sufﬁ-
ciently control pain in a large proportion of patients. Antiviral
therapy may improve HZ symptoms if administered within 72
hours of rash onset, but antiviral drugs are often not prescribed,
because patients do not present sufﬁciently early after disease
onset. The incidence of HZ (and therefore of PHN) can be expected
to increase as the: (1) mean age of the population continues to rise;
(2) prevalence of malignancies and autoimmune diseases in-
creases; and (2) use of immunosuppressant therapies increases.
Furthermore, the widespread introduction of varicella immuniza-
tion programs among children may result in fewer opportunities
for boosting immunity through exogenous exposure to wild-type
virus. This may lead to an increased incidence of HZ and PHN in
adults, until the pool of individuals infected by wild-type VZV is
reduced. However, no increase in HZ incidence that can be attrib-
uted to routine varicella vaccination, which has been in place since
1996, has been observed in the US.77 Prevention of PHN through
vaccination would seem to be a cost-effective alternative, because
there is insufﬁcient evidence that antiviral therapy can prevent the
development of PHN.Acknowledgments
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